Key facts
- This page summarizes Stephen Gordon's Form 4 filing for TransMedics Group, Inc. (TMDX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2022, 16:45.
Stephen Gordon - 22 Feb 2022 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- TMDX
- Reported as of
- 22 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2022, 16:45:29 UTC
- Prior SEC filing
- 09 Sep 2021
- Next SEC filing
- 06 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Stephen Gordon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Gordon filed Form 4 for TransMedics Group, Inc. (TMDX) on 24 Feb 2022.
Change
- Previous filing in this sequence was filed on 09 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TMDX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +52,000
- Change %
- Price
- $0.000000
- Shares after
- 52,000
- Date
- 22 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,000
- Exercise price
- $13.28
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026.